Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE st (Q43208808)

From Wikidata
Jump to navigation Jump to search
scientific article published in March 2010
edit
Language Label Description Also known as
English
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE st
scientific article published in March 2010

    Statements

    Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE st (English)
    Jaime Andrade-Villanueva
    Juan Echevarria
    Ploenchan Chetchotisakd
    Jorge Corral
    Neal David
    Graeme Moyle
    Marco Mancini
    Lisa Percival
    Rong Yang
    Victoria Wirtz
    Max Lataillade
    Judith Absalon
    Donnie McGrath
    CASTLE Study Team
    1 March 2010
    323-332

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit